“Go low” or say “No” to aggressive systolic BP goals?
Metadata[+] Show full item record
The SPRINT trial demonstrated the benefits—and risks—of reaching a systolic target <120 mm Hg in non-diabetic patients at high risk for CV events. Here’s who might benefit. Practice changer: Consider treating non-diabetic patients age ≥50 years to a systolic blood pressure (SBP) target <120 mm Hg as compared to <140 mm Hg when the benefits—lower rates of fatal and nonfatal cardiovascular (CV) events and death from any cause—are likely to outweigh the risks from possible additional medication.
Journal of Family Practice, 65(05) 2016: 342-344.